Free Newsletter
Jury in bellwether Fosamax case unable to agree
The jury in the bellwether Fosamax case against Merck said today that they could not reach a decision, but the federal judge presiding over the case sent them back to the deliberation room to keep trying. The jury is to decide whether osteoporosis drug Fosamax caused a woman's osteonecrosis of the jaw--or "jawbone death." The plaintiff is asking for at least $1 million.
The jury has deliberated for about nine hours since first being assigned the case a week ago. "It's very stressful to sit here and an agreement cannot be reached," a juror wrote in one of four notes to the judge informing him they could not decide. "I feel that we never will reach a verdict because everyone has a different opinion."
U.S. District Judge John Keenan is not ready to toss the case out and explained to the jury that the trial is important to both the plaintiff and the drugmaker. This trial is the first of three bellwether trials Merck faces that will greatly impact the roughly 900 Fosamax cases looming.
- more from Bloomberg
Related Articles:
It's jury time in Fosamax jaw-injury case
Bellwether Fosomax trial starts today
Study links Fosamax to jawbone problems
FDA calls 'all clear' on bone meds (2008)
Bisphosphonates may weaken bones (2008)
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: